CRDF - Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
2024-05-21 23:22:53 ET
Summary
- Cardiff Oncology's Onvansertib is a first-in-class oral PLK1 inhibitor that targets difficult-to-treat cancers such as mCRC, mPDAC, SCLC, and TNBC.
- Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival.
- Ongoing Phase 2 trials for Onvansertib in various cancers include collaborations with Pfizer and other prestigious institutions.
- The company is a biotech microcap with a cash runway extending to Q3 2025 and promising upcoming catalysts in 1H 2024.
- I deem CRDF a “speculative buy” due to Onvansertib's promising early data and market potential despite the inherent biotech risks.
...
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data